EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Open access · CC BY-NC-ND 4.0

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

Andrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, Joel M Trugman, Brett Dabruzzo, Jessica Ailani, Richard B Lipton

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14433 ↗

At a glance

Klinische Studie (Phase I) in Headache: The Journal of Head and Face Pain, 2023. Written by Andrew M Blumenfeld and 6 co-authors. Institution: Headache Center of Southern California, Carlsbad, California, USA. Major MEDLINE topics: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders. Cited 17 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AbbVie.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To evaluate potential drug–drug interactions of ubrogepant and atogepant.

Background

Ubrogepant and atogepant, calcitonin gene‐related peptide (CGRP) receptor antagonists, are recently approved drugs for acute and preventive treatment of migraine, respectively. For patients with migraine who are prescribed atogepant for the preventive treatment of migraine, health care providers could prescribe ubrogepant for the acute treatment of breakthrough migraine attacks.

Methods

A phase Ib, multi‐center, open‐label, fixed‐sequence study was conducted in participants diagnosed with migraine for at least 1 year. To assess the primary objective of pharmacokinetic interactions in this phase I trial, the highest United States Food and Drug Administration‐approved individual dose strengths of atogepant (60 mg once daily) and ubrogepant (100 mg) were utilized, with ubrogepant being administered on a fixed‐dose schedule every 3 days, regardless of whether a participant was experiencing a migraine attack. Secondary endpoints included safety and tolerability. Clinical safety measurements were monitored throughout the study.

Results

Of the 31 participants enrolled, 26 completed the study. A single dose of ubrogepant had no statistically significant effect on atogepant pharmacokinetics. Co‐administration of ubrogepant with atogepant resulted in a 19% increase (geometric mean ratio 118.80, 90% confidence interval [CI] 108.69–129.84) in the ubrogepant area under the plasma concentration‐time curve and a 26% increase (geometric mean ratio 125.63, 90% CI 105.58–149.48) in the ubrogepant maximum plasma concentration. These statistically significant changes in ubrogepant exposure were not clinically meaningful, and no new safety concerns were identified for the combination.

Conclusion

The combination use of atogepant and ubrogepant was safe and well tolerated in adult participants with a history of migraine enrolled in the study. Pharmacokinetic changes during co‐administration were not clinically meaningful.

Subjects

MeSH terms (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersAdultHumansDrug InteractionsPyridinesPyrrolesPiperidinesSpiro Compounds

Author keywords

CGRP receptor antagonistsatogepantdrug-drug interactionmigraineubrogepant

Substances

Calcitonin Gene-Related Peptide Receptor AntagonistsubrogepantPyridinesPyrrolesatogepantPiperidinesSpiro Compounds

Authors and institutions

  • Headache Center of Southern California, Carlsbad, California, USA.
  • Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.

Funding

  • AbbVie

Cite

APA

Blumenfeld, A. M., Boinpally, R., De Abreu Ferreira, R., Trugman, J. M., Dabruzzo, B., Ailani, J., & Lipton, R. B. (2023). Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14433

Vancouver

Blumenfeld AM, Boinpally R, De Abreu Ferreira R, Trugman JM, Dabruzzo B, Ailani J, et al. Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14433

BibTeX
@article{Blumenfeld2023,
  author = {Blumenfeld, Andrew M and Boinpally, Ramesh and De Abreu Ferreira, Rosa and Trugman, Joel M and Dabruzzo, Brett and Ailani, Jessica and Lipton, Richard B},
  title = {Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14433}
}
Start for free →